| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
PXS Stock Overview
Pharmaxis Ltd engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide.
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.11 |
| 52 Week High | AU$0.15 |
| 52 Week Low | AU$0.071 |
| Beta | 0.58 |
| 1 Month Change | 0% |
| 3 Month Change | -4.35% |
| 1 Year Change | 18.28% |
| 3 Year Change | -56.86% |
| 5 Year Change | -60.00% |
| Change since IPO | -75.56% |
Recent News & Updates
Shareholders May Not Be So Generous With Pharmaxis Ltd's (ASX:PXS) CEO Compensation And Here's Why
In the past three years, the share price of Pharmaxis Ltd ( ASX:PXS ) has struggled to grow and now shareholders are...
Shareholder Returns
| PXS | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | 0% | -2.5% | -1.7% |
| 1Y | 18.3% | -12.9% | 7.7% |
Return vs Industry: PXS exceeded the Australian Pharmaceuticals industry which returned -12.9% over the past year.
Return vs Market: PXS exceeded the Australian Market which returned 7.7% over the past year.
Price Volatility
| PXS volatility | |
|---|---|
| PXS Average Weekly Movement | 9.4% |
| Pharmaceuticals Industry Average Movement | 8.3% |
| Market Average Movement | 8.5% |
| 10% most volatile stocks in AU Market | 15.3% |
| 10% least volatile stocks in AU Market | 3.6% |
Stable Share Price: PXS is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: PXS's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 63 | Gary Phillips | https://www.pharmaxis.com.au |
Pharmaxis Ltd engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide. The company operates through two segments, Mannitol Respiratory Business and New Drug Development. It offers Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, an airways inflammation test that is used to identify twitchy or hyper-responsive airways, as well as to assist in diagnosing and managing asthma.
Pharmaxis Fundamentals Summary
| PXS fundamental statistics | |
|---|---|
| Market Cap | AU$57.67m |
| Earnings (TTM) | -AU$1.17m |
| Revenue (TTM) | AU$28.29m |
2.0x
P/S Ratio-49.5x
P/E RatioIs PXS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PXS income statement (TTM) | |
|---|---|
| Revenue | AU$28.29m |
| Cost of Revenue | AU$7.84m |
| Gross Profit | AU$20.44m |
| Expenses | AU$21.61m |
| Earnings | -AU$1.17m |
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
Jan 31, 2022
| Earnings per share (EPS) | -0.0022 |
| Gross Margin | 72.28% |
| Net Profit Margin | -4.13% |
| Debt/Equity Ratio | 0% |
How did PXS perform over the long term?
See historical performance and comparisonValuation
Is Pharmaxis undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: PXS (A$0.11) is trading below our estimate of fair value (A$1.39)
Significantly Below Fair Value: PXS is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: PXS is unprofitable, so we can't compare its PE Ratio to the Global Pharmaceuticals industry average.
PE vs Market: PXS is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate PXS's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: PXS has negative assets, so we can't compare its PB Ratio to the AU Pharmaceuticals industry average.
Future Growth
How is Pharmaxis forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
75.3%
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Pharmaxis has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Past Performance
How has Pharmaxis performed over the past 5 years?
5.9%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PXS is currently unprofitable.
Growing Profit Margin: PXS is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: PXS is unprofitable, but has reduced losses over the past 5 years at a rate of 5.9% per year.
Accelerating Growth: Unable to compare PXS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PXS is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (16.2%).
Return on Equity
High ROE: PXS's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Financial Health
How is Pharmaxis's financial position?
Financial Position Analysis
Short Term Liabilities: PXS has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: PXS has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: PXS is debt free.
Reducing Debt: PXS's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable PXS has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: PXS is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 18.9% per year.
Dividend
What is Pharmaxis's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate PXS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate PXS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PXS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PXS's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of PXS's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
9.1yrs
Average management tenure
CEO
Gary Phillips (60 yo)
8.83yrs
Tenure
AU$682,640
Compensation
Mr. Gary Jonathan Phillips, BPharm, MBA has been Chief Executive Officer and Managing Director of Pharmaxis Ltd. since March 12, 2013 and served as its Chief Operating Officer from November 2003 to March 2...
CEO Compensation Analysis
Compensation vs Market: Gary's total compensation ($USD492.92K) is above average for companies of similar size in the Australian market ($USD290.00K).
Compensation vs Earnings: Gary's compensation has increased whilst the company is unprofitable.
Leadership Team
Experienced Management: PXS's management team is seasoned and experienced (9.1 years average tenure).
Board Members
Experienced Board: PXS's board of directors are considered experienced (6.7 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: PXS insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 32%.
Top Shareholders
Company Information
Pharmaxis Ltd's employee growth, exchange listings and data sources
Key Information
- Name: Pharmaxis Ltd
- Ticker: PXS
- Exchange: ASX
- Founded: 1998
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: AU$57.673m
- Shares outstanding: 524.30m
- Website: https://www.pharmaxis.com.au
Number of Employees
Location
- Pharmaxis Ltd
- 20 Rodborough Road
- Frenchs Forest
- New South Wales
- 2086
- Australia
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/01/20 15:52 |
| End of Day Share Price | 2022/01/20 00:00 |
| Earnings | 2021/09/30 |
| Annual Earnings | 2021/06/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.